Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide
- 23 September 2003
- journal article
- case report
- Published by Wolters Kluwer Health in Neurology
- Vol. 61 (6) , 859-861
- https://doi.org/10.1212/01.wnl.0000083985.00343.f2
Abstract
The authors report the clinical, echocardiographic, and pathologic findings in two patients treated with more than 5 mg of pergolide daily who developed symptomatic severe heart failure due to restrictive valvular disease. They also describe the echocardiographic data of another eight patients taking similar doses of pergolide presenting no clinical signs of heart failure. The findings suggest a possible role of high doses of pergolide in inducing restrictive valvular disease.Keywords
This publication has 10 references indexed in Scilit:
- Valvular Heart Disease in Patients Taking PergolideMayo Clinic Proceedings, 2002
- Fibrotic Valvular Heart Disease Subsequent to Bromocriptine TreatmentCardiology in Review, 2002
- Appetite suppressants and valvular heart diseaseCurrent Opinion in Cardiology, 2002
- Pergolide in the Treatment of Patients With Early and Advanced Parkinson's DiseaseClinical Neuropharmacology, 2002
- The effect of pregnancy in Parkinson's diseaseMovement Disorders, 2000
- Valvular Heart Disease Associated with Fenfluramine–PhentermineNew England Journal of Medicine, 1997
- Improvement of Motor Fluctuations in Patients with Parkinson’s Disease Following Treatment with High Doses of Pergolide and Cessation of LevodopaEuropean Neurology, 1997
- High‐dose pergolide monotherapy in the treatment of severe levodopa‐induced dyskinesiasMovement Disorders, 1996
- Cardiac murmurs and endocardial fibrosis associated with methysergide therapyAmerican Heart Journal, 1974
- Development of heart valve lesions during methysergide therapy.BMJ, 1974